News & Events

Press
JenaValve Announces Start of Commercialization of the Trilogy<sup>®</sup> Transcatheter Heart Valve System in the US
April 1, 2026
JenaValve Announces Start of Commercialization of the Trilogy® Transcatheter Heart Valve System in the US
Read More
Press
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System
March 18, 2026
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System
Read More
Press
New, Late-Breaking Results from the ALIGN-AR Trial Published in The Lancet and Presented at PCR London Valves
November 24, 2025
New, Late-Breaking Results from the ALIGN-AR Trial Published in The Lancet and Presented at PCR London Valves
Read More
Press
JenaValve‘s Trilogy™ System Featured in Live Procedure at TCT 2025
November 10, 2025
JenaValve‘s Trilogy™ System Featured in Live Procedure at TCT 2025
Read More
Press
JenaValve Announced ESC Guidelines Recognize TAVI as Class IIb Recommendation for Aortic Regurgitation
September 10, 2025
JenaValve Announced ESC Guidelines Recognize TAVI as Class IIb Recommendation for Aortic Regurgitation
Read More
Press
JenaValve Announces First Patient Enrolled in ARTIST Randomized Controlled Trial (RCT) Evaluating the Trilogy™ System in Aortic Regurgitation (AR)
July 14, 2025
JenaValve Announces First Patient Enrolled in ARTIST Randomized Controlled Trial (RCT) Evaluating the Trilogy™ System in Aortic Regurgitation (AR)
Read More
Press
JenaValve’s Trilogy System Featured in Live Procedures at New York Valves 2025
July 7, 2025
JenaValve’s Trilogy System Featured in Live Procedures at New York Valves 2025
Read More
Press
ALIGN-AR First 500 Patients Data
March 31, 2025
ALIGN-AR First 500 Patients Data
Read More
Videos
TCT 2024: ALIGN-AR 2-year Outcomes
December 16, 2024
TCT 2024: ALIGN-AR 2-year Outcomes
Watch Video
Close Download
The information in this Reimbursement Guide is provided for educational purposes only and is not intended to be coding or billing advice. This coding information is based upon publicly available information and is current as of April 1, 2026 and subject to change without notice. JenaValve Technology, Inc. cannot guarantee that any product or service billed with the codes listed will be covered or, if covered, the listed payment amount will be paid by any payer. It is the responsibility of the provider to select appropriate codes for each patient and to submit appropriate codes, charges, and modifiers for services rendered. Providers should contact insurers to verify correct coding procedures prior to submitting claims related to the use of JenaValve products. In all cases, providers must bill according to the rules, policies and procedures of individual payers. The medical record should document that the product or procedure was medically necessary and furnished or performed as reported. Clinical need, not reimbursement amount, should always drive clinical decision making. If you have any questions about appropriate billing for products or services, please consult your local payer. The information contained in this guide is provided to assist providers in understanding the reimbursement process. It is intended to assist providers in obtaining accurate and appropriate reimbursement for the healthcare services provided. It is not intended to increase or maximize reimbursement by any payer. It is strongly recommended that providers consult with their payer organizations with regard to local reimbursement policies. The information contained herein is provided for information purposes only and represents no statement, promise, or guarantee by JenaValve Technology, Inc. concerning levels of reimbursement, payment, or charge. Similarly, all CPT codes are supplied for information purposes only and represent no statement, promise, or guarantee by JenaValve Technology, Inc. that these codes will be appropriate or that reimbursement will be made. For additional information, please contact us at reimbursement.usa@jenavalve.com.